Hepatitis B Vaccination in Chronic Kidney Disease: Review of Evidence in Non-Dialyzed Patients

Hepatitis Monthly

Volumn 12, Issue 11, 2012, Pages

  Grzegorzewska, Alicja E ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Hepatitis B Virus; Kidney Disease; Vaccination

Indexed keywords

EID: 85103710358     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: 10.5812/hepatmon.7359     Document Type: Review

References (96)

1. Recommendation of the Immunization Practices Advisory Committee (ACIP). Inactivated hepatitis B virus vaccine. MMWR Morb Mortal Wkly Rep. 1982;31(24):317-22, 27-8.
2. Report of the Advisory Group in Hepatitis, Hepatitis B vaccine, guidance on use; 1982; London: Department of health and social security.
3. Jibani MM, Heptonstall J, Walker AM, Bloodworth LO, Howard AJ. Hepatitis B immunization in UK renal units: failure to put policy into practice. Nephrol Dial Transplant. 1994;9(12):1765-8.
4. Cendoroglo Neto M, Draibe SA, Silva AE, Ferraz ML, Granato C, Pereira CA, et al. Incidence of and risk factors for hepatitis B virus and hepatitis C virus infection among haemodialysis and CAPD patients: evidence for environmental transmission. Nephrol Dial Transplant. 1995;10(2):240-6.
5. Miller ER, Alter MJ, Tokars JI. Protective effect of hepatitis B vaccine in chronic hemodialysis patients. Am J Kidney Dis. 1999;33(2):356-60.
6. Finelli L, Miller JT, Tokars JI, Alter MJ, Arduino MJ. National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial. 2005;18(1):52-61.
7. Grzegorzewska AE, Kaczmarek-Leki V, Młot-Michalska M, Niepols-ki L. Seroconversion rate to positivity for antibodies against core antigen of hepatitis B virus and duration of renal replacement therapy. Nephrol Dial Transplant. 2011;26(3):970-6.
8. Johnson DW, Dent H, Yao Q, Tranaeus A, Huang C-C, Han D-S, et al. Frequencies of hepatitis B and C infections among haemodi-alysis and peritoneal dialysis patients in Asia-Pacific countries: analysis of registry data. Nephrology Dialysis Transplantation. 2009;24(5):1598-603.
9. Thanachartwet V, Phumratanaprapin W, Desakorn V, Sahas-sananda D, Wattanagoon Y, Chaiprasert A, et al. Viral hepatitis infections among dialysis patients: Thailand registry report. Ne-phrology (Carlton). 2007;12(4):399-405.
10. Shakhgil’dian IV, Khukhlovich PA, Savin EA, Kuzin SN, Anan’ev VA, Sergeeva NA, et al. [Risk of infection with hepatitis B and C viruses of medical workers, patients in the hemodialysis ward, and vaccine prophylaxis of hepatitis B infection in these popula-tions]. Vopr Virusol. 1994;39(5):226-9.
11. European Best Practice Guidelines.Prevention and management of HBV, HCV and HIV in HD patients. Nephrol Dial Transplant. 2002;17:72-87.
12. Fabrizi F, Dixit V, Bunnapradist S, Martin P. Meta-analysis: the dialysis mode and immunological response to hepatitis B virus vaccine in dialysis population. Aliment Pharmacol Ther. 2006;23(8):1105-12.
13. Grzegorzewska AE, Kurzawska-Firlej D, Swiderski A, de Mezer-Dambek M, Frankiewicz D, Zaremba-Drobnik D, et al. [Infections with hepatitis B virus in hemodialysis units of Wielkopolska]. Przegl Epidemiol. 2008;62(1):29-37.
14. Hashemi B, Mahdavi-Mazdeh M, Abbasi M, Hosseini-Moghaddam SM, Zinat NH, Ahmadi F. Effcacy of HBV vaccination in various stages of chronic kidney disease: is earlier better? Hepat Mon. 2011;11(10):816-20.
15. Pol S, Legendre C, Mattlinger B, Berthelot P, Kreis H. Genetic basis of nonresponse to hepatitis B vaccine in hemodialyzed patients. J Hepatol. 1990;11(3):385-7.
16. Roznovsky L, Tvrdik J, Kabieszova L, Petrousova L, Orsagova I, Hozakova L, et al. [Vaccination against hepatitis B in patients with chronic renal failure--twenty years follow-up]. Vnitr Lek. 2011;57(10):808-14.
17. Sali S, Alavian SM, Hajarizadeh B. Effect of levamisole supplemen-tation on hepatitis B virus vaccination response in hemodialysis patients. Nephrology (Carlton). 2008;13(5):376-9.
18. Tsouchnikas I, Dounousi E, Xanthopoulou K, Papakonstantinou S, Thomoglou V, Tsakiris D. Loss of hepatitis B immunity in hemo-dialysis patients acquired either naturally or after vaccination. Clin Nephrol. 2007;68(4):228-34.
19. Morbidity and Mortality Weekly Report. Recommendations for preventing transmission of infections among chronic hemodi-alysis patients. U.S. Department of Health and Human Services. Centers for Disease Control and Prevention. 2001;50:RR-5.
20. Grzegorzewska AE, Kurzawska-Firlej D, Ratajewski W, Frankie-wicz D, Niepolski L, Kaczmarek A. Antibodies to core antigen of hepatitis B virus in patients on renal replacement therapy: association with demographic, clinical and laboratory data. Nephron Clin Pract. 2010;114(3):c194-203.
21. Sengar DP, McLeish WA, Sutherland M, Couture RA, Rashid A. Hepatitis B antigen (HBAg) infection in a hemodialysis unit. I. HL-A8 and immune response to HBAg. Can Med Assoc J. 1975;112(8):968, 71.
22. Sengar DP, Rashid A, Jindal SL, Christie CJ. HLA antigens in HBsAg infection. Vox Sang. 1979;36(6):353-5.
23. Hashimoto E, Obata H, Nakanishi T, Kaneko A, Kurihara T, Tomi-matsu T, et al. HLA antigens and anti-HBs response to hepatitis B vaccine. Acta Hepatol Jpn. 1985;26.
24. Watanabe H, Matsushita S, Kamikawaji N, Hirayama K, Okumura M, Sasazuki T. Immune suppression gene on HLA-Bw54-DR4­ DRw53 haplotype controls nonresponsiveness in humans to hepatitis B surface antigen via CD8+ suppressor T cells. Hum Im-munol. 1988;22(1):9-17.
25. Alper CA, Kruskall MS, Marcus-Bagley D, Craven DE, Katz AJ, Brink SJ, et al. Genetic prediction of nonresponse to hepatitis B vac-cine. N Engl J Med. 1989;321(11):708-12.
26. Walker M, Szumuness W, Stevens C, Rubinstein P. Genetics of anti-HBs responsiveness. I. HLA-DR7 and non-responsiveness to hepatitis vaccination Transfusion. 1981;21.
27. Hatae K, Kimura A, Okubo R, Watanabe H, Erlich HA, Ueda K, et al. Genetic control of nonresponsiveness to hepatitis B virus vaccine by an extended HLA haplotype. Eur J Immunol. 1992;22(7):1899­ 905.
28. Hohler T, Meyer CU, Notghi A, Stradmann-Bellinghausen B, Schneider PM, Starke R, et al. The influence of major histocom-patibility complex class II genes and T-cell Vbeta repertoire on response to immunization with HBsAg. Hum Immunol. 1998;59(4):212-8.
29. Girndt M, Sester U, Sester M, Deman E, Ulrich C, Kaul H, et al. The interleukin-10 promoter genotype determines clinical immune function in hemodialysis patients. Kidney Int. 2001;60(6):2385-91.
30. Grzegorzewska AE, Wobszal P, Jagodzinski PP. Interleukin-18 promoter polymorphism and development of antibodies to surface antigen of hepatitis B virus in hemodialysis patients. Kidney Blood Press Res. 2012;35(1):1-8.
31. Grzegorzewska AE, Wobszal PM, Mostowska A, Jagodzinski PP. Antibodies to hepatitis B virus surface antigen and interleukin 12 and interleukin 18 gene polymorphisms in hemodialysis pa-tients. BMC Nephrol. 2012;13:75.
32. Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G. Meta-anal-ysis: the effect of age on immunological response to hepatitis B vaccine in end-stage renal disease. Aliment Pharmacol Ther. 2004;20(10):1053-62.
33. Jadoul M, Goubau P. Is anti-hepatitis B virus (HBV) immunization successful in elderly hemodialysis (HD) patients? Clin Nephrol. 2002;58(4):301-4.
34. Shatat HZ, Kotkat AM, Farghaly AG. Immune response to hepatitis B vaccine in haemodialysis patients. J Egypt Public Health Assoc. 2000;75(3-4):257-75.
35. Stevens C, Alter H, Taylor P, Zang E, Harley E, Szmuness W. The Dialysis Vaccine Trial Study Group: Hepatitis B vaccine in patients receiving hemodialysis. N Engl J Med. 1984;311:496-501.
36. Brown CM, Donlon S, O’Kelly P, Casey AM, Collier C, Conlon PJ, et al. A prospective study of hepatitis B vaccination-a comparison of responders versus nonresponders. Ren Fail. 2011;33(3):276-9.
37. Fernandez E, Betriu MA, Gomez R, Montoliu J. Response to the hepatitis B virus vaccine in haemodialysis patients: influence of malnutrition and its importance as a risk factor for morbidity and mortality. Nephrol Dial Transplant. 1996;11(8):1559-63.
38. Navarro JF, Teruel JL, Mateos ML, Marcen R, Ortuno J. Antibody level after hepatitis B vaccination in hemodialysis patients: influence of hepatitis C virus infection. Am J Nephrol. 1996;16(2):95-7.
39. Ahuja TS, Kumar S, Mansoury H, Rodriguez H, Kuo YF. Hepatitis B vaccination in human immunodeficiency virus-infected adults receiving hemodialysis. Kidney Int. 2005;67(3):1136-41.
40. Alavian SM, Tabatabaei SV. The effect of diabetes mellitus on immunological response to hepatitis B virus vaccine in individuals with chronic kidney disease: A meta-analysis of current litera-ture. Vaccine. 2010;28(22):3773-7.
41. Zitt E, Sprenger-Mahr H, Knoll F, Neyer U, Lhotta K. Vitamin D deficiency is associated with poor response to active hepatitis B immunisation in patients with chronic kidney disease. Vaccine. 2012;30(5):931-5.
42. Contin C, Pitard V, Delmas Y, Pelletier N, Defrance T, Moreau JF, et al. Potential role of soluble CD40 in the humoral immune response impairment of uraemic patients. Immunology. 2003;110(1):131-40.
43. Seaworth B, Drucker J, Starling J, Drucker R, Stevens C, Hamilton J. Hepatitis B vaccines in patients with chronic renal failure before dialysis. J Infect Dis. 1988;157(2):332-7.
44. Agarwal SK, Irshad M, Dash SC. Comparison of two schedules of hepatitis B vaccination in patients with mild, moderate and se-vere renal failure. J Assoc Physicians India. 1999;47(2):183-5.
45. DaRoza G, Loewen A, Djurdjev O, Love J, Kempston C, Burnett S, et al. Stage of chronic kidney disease predicts seroconversion after hepatitis B immunization: earlier is better. Am J Kidney Dis. 2003;42(6):1184-92.
46. Bel’eed K, Wright M, Eadington D, Farr M, Sellars L. Vaccination against hepatitis B infection in patients with end stage renal dis-ease. Postgrad Med J. 2002;78(923):538-40.
47. Pippi F, Bracciale L, Stolzuoli L, Giaccherini R, Montomoli E, Gen-tile C, et al. Serological response to hepatitis B virus vaccine in HIV-infected children in Tanzania. HIV Med. 2008;9(7):519-25.
48. Joint Committee on Vaccination, Immunization, Great Britain. Dept. of Health. Immunisation against infectious disease. London: H.M.S.O.; 1988.
49. Great Britain. Dept. of Health. Immunisation Against Infectious Dis-ease. London: H.M. Stationery Offce; 1990.
50. Ahmadi F, Ramezani M, Razeghi E, Ranjbarnovin N, Khazaeipour Z. A randomized controlled trial of two schedules of hepatitis B vaccination in predialysed chronic renal failure patients. Hepat Mon. 2012;12(5):344-8.
51. Jungers P, Chauveau P, Courouce AM, Abbassi A, Devillier P, Marie FN, et al. [Recombinant vaccine and extracting vaccine against hepatitis B in patients with kidney insuffciency: comparative immunogenicity]. Presse Med. 1994;23(6):277-80.
52. Loza Munarriz C, Depaz Dolores M, Suarez Jara M, Loza Munarriz R, Valenzuela Cordova R, Bravo Tejada J, et al. [Rate of serological markers of hepatitis B and C viruses in first-time users of the hemodialysis program at Hospital Nacional Cayetano Heredia (HNCH)]. Rev Gastroenterol Peru. 2005;25(4):320-7.
53. McMahon BJ, Bruden DL, Petersen KM, Bulkow LR, Parkinson AJ, Nainan O, et al. Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up. Ann Intern Med. 2005;142(5):333-41.
54. Avazova D, Kurbanov F, Tanaka Y, Sugiyama M, Radchenko I, Ru-ziev D, et al. Hepatitis B virus transmission pattern and vaccination effciency in Uzbekistan. J Med Virol. 2008;80(2):217-24.
55. West DJ, Calandra GB. Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination. Vaccine. 1996;14(11):1019-27.
56. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatol-ogy. 2009;50(3):661-2.
57. Dukes CS, Street AC, Starling JF, Hamilton JD. Hepatitis B vaccination and booster in predialysis patients: a 4-year analysis. Vac-cine. 1993;11(12):1229-32.
58. Lefebure AF, Verpooten GA, Couttenye MM, De Broe ME. Immu-nogenicity of a recombinant DNA hepatitis B vaccine in renal transplant patients. Vaccine. 1993;11(4):397-9.
59. Lindsay KL, Herbert DA, Gitnick GL. Hepatitis B vaccine: low post-vaccination immunity in hospital personnel given gluteal injec-tions. Hepatology. 1985;5(6):1088-90.
60. Ukena T, Esber H, Bessette R, Parks T, Crocker B, Shaw FE, Jr. Site of injection and response to hepatitis B vaccine. N Engl J Med. 1985;313(9):579-80.
61. McNulty CA, Bowen JK, Williams AJ. Hepatitis B vaccination in predialysis chronic renal failure patients a comparison of two vaccination schedules. Vaccine. 2005;23(32):4142-7.
62. Good Practice Guidelines for Renal Dialysis/Transplantation Units Prevention and Control of Blood-borne Virus Infection. London: Department of Health; 2002.
63. Landreneau MD, DeVault GA, Rohr MA, Kilpatrick JS, King JW, Rhynes VK, et al. Transmission of hepatitis B by renal transplan­ tation despite active immunization with hepatitis B vaccine. Clin Transplant. 1988;2:265-9
64. Lombardi M, Pizzarelli F, Righi M, Cerrai T, Dattolo P, Nigrelli S, et al. Hepatitis B vaccination in dialysis patients and nutritional status. Nephron. 1992;61(3):266-8.
65. Su WJ, Ho MC, Ni YH, Chen HL, Hu RH, Wu YM, et al. High-titer antibody to hepatitis B surface antigen before liver transplantation can prevent de novo hepatitis B infection. J Pediatr Gastroenterol Nutr. 2009;48(2):203-8.
66. Fabrizi F, Martin P. Hepatitis B virus infection in dialysis patients. Am J Nephrol. 2000;20:1-11.
67. Trepo CG, Prince AM. Absence of complete homologous immunity in hepatitis B infection after massive exposure. Ann Intern Med. 1976;85(4):427-30.
68. Hoofnagle JH, Gerety RJ, Smallwood LA, Barker LF. Subtyping of hepatitis B surface antigen and antibody by radioimmunoassay. Gastroenterology. 1977;72(2):290-6.
69. Koziol DE, Alter HJ, Kirchner JP, Holland PV. The development of HBsAg-positive hepatitis despite the previous existence of antibody to HBsAg. J Immunol. 1976;117(6):2260-2.
70. Chabaud M, Depril N, Le Cann P, Leboulleux D, Nandi R, Coll-Seck AM, et al. Detection of hepatitis B virus DNA by polymerase chain reaction in vaccinated and non-vaccinated Senegalese children. Arch Virol Suppl. 1993;8:123-31.
71. Waters JA, Kennedy M, Voet P, Hauser P, Petre J, Carman W, et al. Loss of the common “A” determinant of hepatitis B surface antigen by a vaccine-induced escape mutant. J Clin Invest. 1992;90(6):2543-7.
72. Fabrizi F, Dixit V, Magnini M, Elli A, Martin P. Meta-analysis: intradermal vs. intramuscular vaccination against hepatitis B virus in patients with chronic kidney disease. Aliment Pharmacol Ther. 2006;24(3):497-506.
73. Marangi AL, Giordano R, Montanaro A, De Padova F, Schiavone MG, Dongiovanni G, et al. Hepatitis B virus infection in chronic uremia: long-term follow-up of a two-step integrated protocol of vaccination. Am J Kidney Dis. 1994;23(4):537-42.
74. Somboonsilp W, Eiam-Ong S, Tungsanga K, Tirawatanapong T. Immune response of intradermal hepatitis B vaccination at lower dose versus intramuscular vaccination at double standard dose in predialytic chronic renal failure patients. J Med Assoc Thai. 2003;86(12):1122-7.
75. Milich DR, McLachlan A, Chisari FV, Kent SB, Thorton GB. Immune response to the pre-S(1) region of the hepatitis B surface antigen (HBsAg): a pre-S(1)-specific T cell response can bypass nonre-sponsiveness to the pre-S(2) and S regions of HBsAg. J Immunol. 1986;137(1):315-22.
76. Gerlich WH, Deepen R, Heermann KH, Krone B, Lu XY, Seifer M, et al. Protective potential of hepatitis B virus antigens other than the S gene protein. Vaccine. 1990;8 Suppl:S63-8; discussion S79­ 80.
77. Polito P, Di Lullo L, Iannacci GR, Cecilia A, Galderisi C, Gorini A. [Seroconversion and immune response after anti-HBV vaccination in patients on chronic hemodialysis: comparison of two vaccines]. G Ital Nefrol. 2011;28(5):525-30.
78. Surquin M, Tielemans C, Nortier J, Jadoul M, Peeters P, Ryba M, et al. Anti-HBs antibody persistence following primary vaccination with an investigational AS02(v)-adjuvanted hepatitis B vaccine in patients with renal insuffciency. Hum Vaccin. 2011;7(9):913-8.
79. Tielemans CL, Vlasak J, Kosa D, Billiouw JM, Verpooten GA, Mezei I, et al. Immunogenicity and safety of an investigational AS02(v)­ adjuvanted hepatitis B vaccine in patients with renal insuff-ciency who failed to respond or to maintain antibody levels after prior vaccination: results of two open, randomized, comparative trials. Vaccine. 2011;29(6):1159-66.
80. Fabrizi F, Dixit V, Messa P, Martin P. Hepatitis B virus vaccine in chronic kidney disease: improved immunogenic-ity by adjuvants? A meta-analysis of randomized trials. Vaccine. 2012;30(13):2295-300.
81. Duranti E, Duranti D. Polymethylmethacrylate strengthens antibody response in hemodialysis patients not responding to hepatitis B vaccine: preliminary data. Minerva Med. 2011;102(6):469-74.
82. Brodersen HP, Holtkamp W, Larbig D, Beckers B, Thiery J, Laut-enschlager J, et al. Zinc supplementation and hepatitis B vaccination in chronic haemodialysis patients: a multicentre study. Nephrol Dial Transplant. 1995;10(9):1780.
83. Donati D, Gastaldi L. Controlled trial of thymopentin in hemo-dialysis patients who fail to respond to hepatitis B vaccination. Nephron. 1988;50(2):133-6.
84. Verkade MA, van de Wetering J, Klepper M, Vaessen LM, Weimar W, Betjes MG. Peripheral blood dendritic cells and GM-CSF as an adjuvant for hepatitis B vaccination in hemodialysis patients. Kidney Int. 2004;66(2):614-21.
85. Jungers P, Devillier P, Salomon H, Cerisier JE, Courouce AM. Ran-domised placebo-controlled trial of recombinant interleukin-2 in chronic uraemic patients who are non-responders to hepatitis B vaccine. Lancet. 1994;344(8926):856-7.
86. Sennesael JJ, Van der Niepen P, Verbeelen DL. Treatment with recombinant human erythropoietin increases antibody titers after hepatitis B vaccination in dialysis patients. Kidney Int. 1991;40(1):121-8.
87. Hennig BJ, Fielding K, Broxholme J, Diatta M, Mendy M, Moore C, et al. Host genetic factors and vaccine-induced immunity to hepatitis B virus infection. PLoS One. 2008;3(3):e1898.
88. Petrescu L, Stancu S, Tardei G, Santimbrean C, Penescu M, Mirces-cu G. Tuberculin skin test, interferon-gamma assay, and T cells subpopulations in hemodialysis patients. J Ren Nutr. 2010;20(5 Suppl):S109-17.
89. Tang LL, Liu KZ. Recent advances in DNA vaccine of hepatitis vi-rus. Hepatobiliary Pancreat Dis Int. 2002;1(2):228-31.
90. Kim JJ, Nottingham LK, Tsai A, Lee DJ, Maguire HC, Oh J, et al. An-tigen-specific humoral and cellular immune responses can be modulated in rhesus macaques through the use of IFN-gamma, IL-12, or IL-18 gene adjuvants. J Med Primatol. 1999;28(4-5):214-23.
91. Tominaga K, Yoshimoto T, Torigoe K, Kurimoto M, Matsui K, Hada T, et al. IL-12 synergizes with IL-18 or IL-1beta for IFN-gamma production from human T cells. Int Immunol. 2000;12(2):151-60.
92. Yoshimoto T, Takeda K, Tanaka T, Ohkusu K, Kashiwamura S, Oka-mura H, et al. IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-gamma production. J Immunol. 1998;161(7):3400-7.
93. Channarong S, Mitrevej A, Sinchaipanid N, Usuwantim K, Kulkeaw K, Chaicumpa W. Cloning, protein expression and im-munogenicity of HBs-murine IL-18 fusion DNA vaccine. Asian Pac J Allergy Immunol. 2007;25(4):233-42.
94. Chen JZ, Zhu HH, Liu KZ, Chen Z. Enhancing cellular immune response to HBV M DNA vaccine in mice by codelivery of interleu-kin-18 recombinant. J Zhejiang Univ Sci. 2004;5(4):467-71.
95. Arevalo JA, Washington AE. Cost-effectiveness of prenatal screen-ing and immunization for hepatitis B virus. JAMA: the journal of the American Medical Association. 1988;259(3):365-9.
96. Ginsberg GM, Shouval D. Cost-benefit analysis of a nationwide neonatal inoculation programme against hepatitis B in an area of intermediate endemicity. J Epidemiol Community Health. 1992;46(6):587-94.